Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi is running a long study that compares its new drug frexalimab with sta...

Sanofi’s Frexalimab Kidney Transplant Trial: A Long-Term Bet With Quiet but Real Upside

An announcement from Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) is now available. Sany Heavy Equipment International Holdings re...

Sany Heavy Equipment Revenue Rises but Profits Fall in First Quarter 2026

An update from Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) is now available. Polestar Automotive Holding UK PLC, a pure-p...

Polestar Sets June 26 AGM as It Prepares Major EV Model Offensive

Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed ...

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, called “A Prospective, Observati...

Real-World Dupixent Data in Canada: What Regeneron and Sanofi Investors Should Watch

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi (SNY) is running a mid-stage trial called “A Randomized, Double-blinde...

Sanofi’s SAR445399 Lung Trial Moves Ahead: What Investors Should Watch

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Carnival (CCL), Wendy’s (WEN) and Polestar ...

Analysts Have Conflicting Sentiments on These Consumer Cyclical Companies: Carnival (CCL), Wendy’s (WEN) and Polestar Automotive Holding UK (PSNY)

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. equity market, rose 0.66% at Friday’s open as investors reacted to geopol...

Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) has issued an update. Sany Heavy Equipment International Holdings Company Limited has...

Sany Heavy Equipment Sets May Board Meeting to Review First-Quarter 2026 Results

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has provided an update. On May 7, 2026, Polestar reported selected preliminar...

Polestar Posts Record Q1 2026 Volumes but Deeper Losses Amid Tariff and Pricing Pressure

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. equity market, rose 0.76% at the market open on Wednesday. Investor senti...

Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/6/26?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. equity market, rose 0.53% in pre-market trading on Tuesday. Investors lar...

Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/5/26?

Vanguard Total Stock Market ($VTI), which tracks the broader U.S. market, was little changed in pre-market trading on Monday, down about 0.014% as ...

Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 5/4/26?

In a report released on April 29, Jose Porta from Kepler Capital maintained a Sell rating on Naturgy Energy Group, S.A., with a price target of €24...

Kepler Capital  Sticks to Its Sell Rating for Naturgy Energy Group, S.A. (0NPV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fulcrum Therapeutics (FULC) and Sanofi (SNYNF) with ...

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Sanofi (OtherSNYNF)

Sanofi ( ($SNY) ) just unveiled an update. In April 2026, Sanofi reported new phase 4 data showing its protein‑based, non‑mRNA COVID‑19 vaccine Nuv...

Sanofi Strengthens Vaccine and Specialty Care Portfolio With New Nuvaxovid Data and Multiple April 2026 Approvals

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. market, is down 0.014% at Monday’s open as markets prepare for major tech...

Market Cap	$106.21B	P/E Ratio	8.87
52W High	$53.36	52W Low	$42.78
Div Yield	241.9%	Payout Ratio	0.0%
EPS Growth 3Y	0.0%	52W Position	12.9%
Overall Score	54	Value Score	80
Quality Score	55	Technical Score	27

EPS Current Est	$4.98	EPS Next Est	$5.21
EPS Growth Est	+4.6%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$44.15	-0.32%	2.54M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$44.15	-0.3%	2.54M
3
4
5
6

SNY

SNY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sanofi Data in Excel

Get Sanofi Data in Excel